does melanotan 2 work: Frequently asked questions

MT-2 degrades through oxidation of methionine residues and cyclization at the lactam bridge when stored in solution above 4°C or exposed to light. Reconstitute MT-2 in bacteriostatic water with 0.1% acetic acid to maintain pH 4.5–5.5, store at 2–4°C in amber vials, and use within 14 days. Freeze-thaw cycles denature the peptide structure irreversibly. Aliquot reconstituted MT-2 into single-use volumes immediately after mixing.

Run parallel experiments with a selective MC4R agonist and compare dose-response curves. If MT-2 and the selective agonist produce identical effects at equipotent MC4R doses, the outcome is MC4R-mediated. If MT-2 shows enhanced or prolonged effects, MC3R or MC5R co-activation is contributing. Use selective antagonists for those receptors to confirm their involvement.

Use receptor knockout models or selective antagonists to dissect individual contributions. For example, MC3R knockout mice treated with MT-2 will show only MC1R/MC4R/MC5R effects, isolating MC3R's role by subtraction. Alternatively, co-administer MT-2 with an MC3R-selective antagonist to block that receptor while preserving others. This approach works when genetic models aren't available.

Verify three variables before increasing dose: (1) Was the peptide stored correctly both before and after reconstitution? (2) Are you injecting subcutaneously into fatty tissue, not intramuscularly? (3) What is your baseline Fitzpatrick skin type? Individuals with very fair skin (type I–II) may require 10–14 days to observe visible pigmentation due to low melanocyte density. If storage and technique are correct, consider minimal UV exposure (10–15 minutes) to provide the baseline melanin substrate MT2 amplifies. The peptide accelerates pigmentation but does not create melanin ex nihilo in the absence of any UV.

Nausea and flushing are on-target MC4R effects, not allergic reactions. They indicate dose is too high relative to your receptor sensitivity. Reduce dose by 50% for the next administration and titrate upward more gradually. Many users start at 0.25mg daily rather than 0.5–1.0mg to minimize GI effects. The nausea typically resolves within 2–4 hours as plasma concentration declines. Taking MT2 in the evening before bed allows users to sleep through peak side effect windows.

Discard the vial and do not use it. Temperature excursions above 8°C denature peptide structure irreversibly. The MT2 may appear unchanged but will have lost binding affinity at melanocortin receptors. Administering degraded peptide produces no tanning or appetite suppression and wastes the dose. Refrigeration at 2–8°C must begin immediately after reconstitution.

No. Eumelanin already synthesized remains in keratinocytes for the natural skin cell turnover cycle, which is approximately 28–40 days. Pigmentation fades gradually as melanocytes return to baseline tyrosinase activity and UV exposure ceases. Discontinuing MT2 does not cause sudden pigment loss. The tan diminishes over 4–8 weeks depending on exfoliation rate and sun exposure habits.